Topic: biosimilars

Teva teams up on biosims with Celltrion

Teva and Korea’s Celltrion have come together to form a biosims commercial pact as the Israeli generics giant aims for deeper ties in the growing biologic copies space--and a new partner after Lonza backed away in 2013.

Samsung Bioepis races rivals as EMA accepts Herceptin biosim app

A month after Mylan and Biocon saw the EMA accept their marketing application for a copycat version of Roche’s major blockbuster cancer med Herceptin (trastuzumab)--the first to do so--Samsung Bioepis says it too has now notched that regulatory milestone as the companies race to market.